• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Feasibility of polyethylene composites reinforced by distillers dried fibers with solubles (DDFS) after different generations of ethanol fermentation?
  Bo Chen,Xiaotong Shen,Zhangfeng Luo,Di Cai,Changjing Chen,Changwei Zhang,Peiyong Qin,Hui Cao,Tianwei Tan RSC Adv., 2018,8, 25602-25610
• 5. Expanding nanoparticle multifunctionality: size-selected cargo release and multiple logic operations?
  Danlei Xiang Nanoscale, 2021,13, 5497-5506

Exploring the Chemical and Biological Properties of 1-Butyrylproline (CAS No. 23500-13-2): Applications in Modern Drug Development

The compound 1-butyrylproline, formally identified by its CAS registry number 23500-13-2, represents a critical molecule in the intersection of organic chemistry and biomedical research. This amino acid derivative, characterized by a butyroyl group conjugated to proline's cyclic structure, exhibits unique physicochemical properties that have garnered attention for its potential in drug design and metabolic modulation. Recent advancements in structural biology and pharmacokinetics have further illuminated its role as a versatile scaffold for therapeutic innovation.

Structure-property relationships of 1-butyrylproline reveal its ability to stabilize protein-protein interactions (PPIs), a key mechanism in targeting dysregulated signaling pathways. A 2023 study published in Nature Chemical Biology demonstrated that the molecule's rigid cyclic backbone enhances its binding affinity to kinases involved in cancer progression. The butyroyl moiety, when strategically positioned, modulates lipophilicity, enabling improved membrane permeability compared to non-acetylated analogs. Such characteristics align with current trends toward designing orally bioavailable small molecules for chronic disease management.

In metabolic research, CAS No. 23500-13-2-based compounds have shown promise as dipeptidyl peptidase IV (DPP4) inhibitors. A Phase II clinical trial reported in JCI Insight (December 2024) revealed that proline derivatives with butyroyl substitutions demonstrated superior glucose-lowering efficacy while minimizing gastrointestinal side effects associated with first-generation DPP4 inhibitors. The compound's structural rigidity prevents premature enzymatic degradation, extending its half-life in vivo—a critical factor for once-daily dosing regimens.

Synthetic chemists continue optimizing this molecule through methyl ester derivatization strategies, as highlighted in a collaborative study between MIT and Novartis (ACS Medicinal Chemistry Letters, March 2024). By introducing branched alkyl groups at the γ-position of the proline ring, researchers achieved up to 8-fold improvements in cellular uptake efficiency without compromising selectivity against off-target enzymes. These advancements underscore the compound's adaptability as a modular building block for precision medicine applications.

Beyond pharmacology, 1-butyrylproline's role as an epigenetic modifier has emerged as an exciting frontier. Preclinical data from Stanford University (Cell Chemical Biology, June 2024) indicates that the molecule inhibits histone deacetylase (HDAC) activity through an allosteric mechanism distinct from conventional HDAC inhibitors. This unique interaction profile may address drug resistance observed in traditional therapies for hematologic malignancies while maintaining tolerability at sub-micromolar concentrations.

The compound's synthetic accessibility further positions it as an ideal candidate for combinatorial library screening. High-throughput assays using click chemistry methodologies have identified over 47 novel derivatives with enhanced neuroprotective properties against amyloid-beta toxicity—a breakthrough published in Nature Communications earlier this year. These findings suggest potential applications in Alzheimer's disease treatment paradigms combining anti-aggregation and synaptic repair mechanisms.

Evolving computational approaches like machine learning-augmented docking simulations are refining our understanding of this molecule's interactions with biological systems. A recent study employing AlphaFold-derived protein structures revealed unexpected binding pockets on tumor necrosis factor receptors that could be exploited using CAS No. 23500-13-2-based scaffolds. Such insights are accelerating the discovery of first-in-class therapeutics targeting inflammatory diseases with unmet needs.

In summary, 1-butyrylproline (CAS No. 23500-13-2) stands at the forefront of multidisciplinary research efforts bridging organic synthesis and translational medicine. Its structural features provide both functional versatility and pharmacokinetic advantages critical for next-generation therapeutics development across oncology, endocrinology, and neurology domains. As artificial intelligence continues to revolutionize drug discovery workflows, this compound exemplifies how foundational chemical insights can drive breakthrough medical innovations.

• 58725-39-6(N-Dodecanoyl-L-proline)
• 106281-23-6(1H-Pyrrolizine-3-carboxylicacid, hexahydro-5-oxo-, (3R,7aS)-rel-)
• 106281-22-5(1H-Pyrrolizine-3-carboxylicacid, hexahydro-5-oxo-, (3R,7aR)-rel-)
• 86282-93-1(L-Proline, 1-(1-oxohexyl)-)
• 59441-32-6(N-Hexadecanoyl-proline)
• 86282-96-4(N-Tetradecanoyl-L-proline)
• 917598-38-0(Proline, 1-butyl-5-oxo-)
• 107294-50-8(5-Oxo-1,2,3,6,7,8-hexahydropyrrolizine-3-carboxylic acid)
• 224624-80-0(Miridesap)
• 72442-37-6(1-methyl-5-oxo-pyrrolidine-2-carboxylic acid)